MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Effects of a Aquatic Dual Task Activity Program on the Quality of Life and Activities of Daily Living in Individuals with Parkinson’s Disease

    A. Silva, V. Israel (Curitiba, Brazil)

    Objective: To verify the effect of an aquatic Dual Task (DT) aquatic exercise program on quality of life (QOL), Activities of Daily Living activities (ADL) of…
  • 2017 International Congress

    Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

    K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

    Objective:  This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…
  • 2017 International Congress

    5-year results from the NSTAPS trial: comparing bilateral deep brain stimulation of the globus pallidus pars interna versus the subthalamic nucleus for advanced Parkinson’s disease.

    J. Boel, V. Odekerken, P. vanden Munckhof, G. Geurtsen, M. Figee, J. Dijk, R. de Haan, B. Schmand, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

    Objective: Comparing motor, cognitive, and psychiatric outcome 5 years after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) and the subthalamic…
  • 2017 International Congress

    Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.

    S. Ray, D. Burdick, A. Griffith, P. Agarwal (Kirkland, WA, USA)

    Objective: To report enrollment and tolerability data of mirabegron treatment in PD patients with OAB. Background: Lower urinary tract symptoms in PD have an estimated…
  • 2017 International Congress

    ON-time evolution following one-year open-label opicapone: BIPARK-I study

    J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, I. Oliveira, B. Hernandez, F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…
  • 2017 International Congress

    Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study

    C. Kenney, A. Glass, W. Olanow (Ardsley, NY, USA)

    Objective: To evaluate whether patient perceived improvement of Parkinson’s disease (PD) symptoms was associated with improvement in efficacy endpoints (mean daily OFF time and ON…
  • 2017 International Congress

    Cardiac 123I-MIBG Scintigraphy, olfactory testing and transcranial sonography for differentiating between Parkinson’s disease and atypical parkinsonian syndromes during the early stage

    h. fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

    Objective: To evaluate the utility of the combined use of cardiac metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS)…
  • 2017 International Congress

    Post-movement beta rebound inhibits future movement

    E. Rhodes, A. Kharko, W. Gaetz, S. Hall (Plymouth, United Kingdom)

    Objective: To evaluate the potential inhibitory effect of post-movement beta rebound (PMBR) on future movement production. Background: Changes in the cortical power of beta oscillations within the…
  • 2017 International Congress

    Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.

    C. Lambert, O. Williams, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)

    Objective: Using the Progressive Parkinson’s Initiative (PPMI) data, clinical and structural differences between individuals destined to develop PD cognitive impairment was defined. Background: Cognitive dysfunction…
  • 2017 International Congress

    Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI

    K. Schindlbeck, A. Vo, Y. Ma, S. Peng, K. Poston, H. Hurtig, N. Dahodwala, D. Eidelberg (Manhasset, NY, USA)

    Objective: To validate Parkinson’s Disease-related network topography characterized with resting-state functional MRI (rs-fMRI) in two multicenter based cohorts of idiopathic Parkinson’s disease (IPD) patients.  Background:…
  • « Previous Page
  • 1
  • …
  • 104
  • 105
  • 106
  • 107
  • 108
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley